We identify a compartmentalized signaling system that identifies a functional role for the GTP exchange factor, exchange protein activated by cAMP (EPAC) coupled to Rap2 in the nucleus. In this system, cAMP regulates the nuclear/cytoplasmic trafficking of DNA-dependent protein kinase (DNA-PK), a critical kinase that acts to repair double-stranded breaks (DSBs) in damaged DNA and to phosphorylate the cell survival kinase, PKB/Akt. Intersecting regulatory inputs for cAMP employ EPAC to transduce positive effects, namely the Rap2-dependent nuclear exit and activation of DNA-PK, whereas protein kinase A (PKA) provides the negative input by antagonizing these actions. We identify this as a compartmentalized regulatory system where modulation of cAMP input into the stimulatory, EPAC and inhibitory, PKA intersecting arms is provided by spatially discrete, cAMP degradation systems. The distribution of DNA-PK between nuclear and cytoplasmic compartments can thus potentially be influenced by relative inputs of cAMP signaling through the EPAC and PKA pathways. Through this signaling system EPAC activation can thereby impact on the Ser-473 phosphorylation status of PKB/Akt and the repair of etoposide-induced DSBs.
C
yclic AMP (cAMP) provided the paradigm for the second messenger concept and is appreciated as a ubiquitous and critical intracellular signaling molecule that regulates many key processes in all cell types (1) (2) (3) (4) (5) . It is now well established that cAMP signaling is compartmentalized in cells, with cAMP gradients being interpreted through the selective activation of distinct subpopulations of effector molecules (2, 4, 6) . For example, spatially discrete subpopulations of protein kinase A (PKA) are generated by anchor proteins (AKAPs), which sequester and target PKA to specific intracellular sites (2, 4, 7) . cAMP gradients can be formed and shaped through targeted degradation by spatially constrained phosphodiesterases, with members of the phosphodiesterase-4 (PDE4) family providing a key role in many cell types (8) (9) (10) (11) . Indeed, specific PDE4 isoforms can be targeted to critical signaling scaffold proteins, such as ␤-arrestin (12), RACK1 (13) , and DISC1 (14) , thereby regulating distinct processes.
Exchange protein activated by cAMP 1 and 2 (EPAC1 and EPAC2, respectively) are cAMP signaling effectors, acting as a guanine nucleotide exchange factor for the GTPases, Rap1 and Rap2 (1) . They differ structurally in that EPAC2 has an additional cAMP-binding domain. Through Rap1, EPAC regulates key processes such as the integrity of endothelial cell junctions, integrin-mediated cell adhesion (15) , and IL-3 (16) signaling. In contrast, little is known concerning the functional significance of EPAC signaling through Rap2. EPAC not only distributes through the cytosol and at the plasma membrane (1) but also locates at the nuclear membrane and within the nucleus (17) , although the functional significance of these actions is unknown.
Here, we describe the action of EPAC on a nuclear event that targets DNA-dependent protein kinase (DNA-PK), an enzyme that provides a key part of the DNA repair systems essential for the maintenance of chromosomal integrity (18) . Thus, cAMP signaling, via EPAC coupled to Rap2, triggers the nuclear exit of DNA-PK, whereas nuclear reentry of DNA-PK is promoted by PKA. This system exemplifies convergent signaling through the EPAC and PKA systems where spatially segregated populations of cAMP-degrading enzymes can, potentially, gate the cAMP input threshold through each arm.
Results
Opposing cAMP Signaling Systems, Provided by PKA and EPAC, Regulate DNA-PK Nuclear Entry and Exit in Various Cell Types. In resting HEK-B2 cells, a stable cloned HEK cell line transfected to express ␤ 2 -adrenoceptors (␤ 2 -AR) (12) , DNA-PK is localized to the nucleus (Fig. 1A) . However, challenge with the adenylyl cyclase activator forskolin causes a dramatic translocation of DNA-PK to the cytoplasm ( Fig. 1 A and E) . This effect is EPAC-mediated, being mimicked by challenging cells with the selective EPAC agonist, 8pMeOPT-2Ј-O-Me-cAMP (PMTcAMP), which is unable to activate PKA (1, 19) . Such DNA-PK translocation is apparent by 5 min, complete by 10 min, and is fully reversible upon PMT-cAMP washout [ Fig. 1 B and C and supporting information (SI) Fig. S1a ].
Some 68% of total cAMP PDE activity in these cells is contributed by PDE4, which can be ablated by the selective inhibitor, rolipram (20) . The phenotypic response seen by stimulating cAMP generation alone is invariably potentiated by additionally inhibiting cAMP degradation to achieve supraelevation of cAMP levels. In HEK-B2 cells, basal adenylyl cyclase activity is low (20) , and inhibition of PDE4 with rolipram has, unsurprisingly, little effect on either intracellular cAMP levels (Fig. S1b) or DNA-PK localization ( Fig. 1 D and E) . However, in forskolin-treated cells, although rolipram increased intracellular cAMP levels (Fig. S1b) , surprisingly it compromises DNA-PK nuclear exit ( Fig. 1 D and E) . Such inhibitory action of rolipram is specific, being mimicked by a chemically distinct PDE4-selective inhibitor (Ro20-1724) and by the nonselective PDE inhibitor, 3-isobutyl-1-methylxanthine (data not shown).
These observations suggest that although cAMP, through EPAC, facilitates nuclear exit of DNA-PK it can also abrogate this process through a distinct route. In HEK-B2 cells, cAMP input into this inhibitory arm is gated by PDE4 activity and only unmasked upon PDE4 inhibition in the face of adenylyl cyclase activation by forskolin. Because PKA provides a major cAMP effector, we set out to determine whether it provides the inhibitory arm of this process. Indeed, treatment with either the PKA-selective inhibitor, KT5720 or expression of the PKA inhibitor, PKI (2) conferred rescue, allowing combined forskolin ϩ rolipram challenge to elicit DNA-PK nuclear exit ( Fig. 1 D and E and Fig. S1c ). Thus, nuclear/cytoplasmic translocation of DNA-PK is under dual control by cAMP, with EPAC activation promoting nuclear exit while PKA promotes its nuclear entry (Fig. 1F) .
Activating adenylyl cyclase through a G protein-coupled receptor exerts a similar action because challenge with the ␤-agonist isoprenaline, which activates ␤ 2 -ARs in these cells (20) , also triggers DNA-PK nuclear exit (Fig. S1d) . This effect was also ablated when rolipram was added with isoprenaline.
We set out to determine whether cAMP might similarly inf luence DNA-PK nuclear/cytoplasmic distribution in other cell types. Presuming that specific cell types possess the necessary regulatory machinery for cAMP to act then, in resting conditions, differences in the relative basal inputs through EPAC and PKA will likely inf luence how DNA-PK is distributed between the nucleus and cytoplasm. Indeed, in resting HeLa cells, DNA-PK is found in both the cytoplasm and the nucleus rather than being exclusively nuclear-localized as in HEK-B2 cells. Here, PMT-cAMP challenge causes only a small increase in nuclear exit of DNA-PK (Fig. S2 a and b) . Based on our model (Fig. 1F) , this might indicate that under basal conditions there is dynamic cycling of DNA-PK caused by combined EPAC-driven nuclear exit and PKA-driven nuclear reentry. Consistent with this, treating cells with KT5720 to inhibit PKA and block nuclear entry enhanced DNA-PK accumulation in the cytoplasm as did treatment with EPAC agonist ϩ KT5720. An extended time course shows that treatment of HeLa cells with PMT-cAMP ϩ KT5720 causes stable nuclear exit of DNA-PK for at least 3 h (Fig. S2c) .
In both mouse embryo fibroblasts (MEFs) and A10 smooth muscle cells, DNA-PK is also distributed between the cytoplasm and nucleus. Again, PMT-cAMP promoted little DNA-PK accumulation in the cytoplasm but its action was amplified by KT5720-mediated PKA inhibition (Fig. S3) . In human neuronal SA121-derived cells, DNA-PK was located predominantly in the nucleus, and exit was induced by PMT-cAMP challenge (Fig.  S4 ). These data indicate that EPAC activation can promote DNA-PK exit in various cell types.
EPAC is found associated with the plasma membrane and punctate structures through the cytoplasm and the nucleus in HEK-B2 cells (Fig. S5a) . Although this pattern appears little changed by PMT-cAMP challenge, EPAC nuclear accumulation occurs in cells treated with the chromosome region maintenance 1 (CRM1)-mediated nuclear export inhibitor, leptomycin B (Fig.  S5a) , suggesting that EPAC undergoes nuclear/cytoplasmic trafficking. However, leptomycin B treatment did not affect the ability of PMT-cAMP to elicit DNA-PK nuclear exit (Fig. S5b) . This indicates that DNA-PK does not exit the nucleus via a CRM-dependent pathway and implies that nuclear-entrapped EPAC is fully functional in eliciting DNA-PK nuclear exit.
Consistent with PMT-cAMP acting through EPAC, siRNAmediated knockdown of EPAC (Fig. S6a) prevented it from promoting DNA-PK nuclear exit in HEK-B2 cells (Fig. S6b) , which, unlike wild-type HEK cells, exhibit immunologically detectable levels of EPAC and detectable EPAC transcripts.
EPAC Couples to Rap2 to Facilitate DNA-PK Nuclear Exit. Rap1 and Rap2 are spatially segregated in HEK-B2 cells, with Rap1 restricted to the cytoplasm and Rap2 restricted to the nucleus (Fig. S6c) , suggesting a functional correlate. Indeed, selective siRNA-mediated knockdown of Rap2 negates the ability of PMT-cAMP to trigger DNA-PK nuclear exit, whereas knockdown of Rap1 does not ( Fig. 2 and Fig. S6 d and e). Given that leptomycin B entraps EPAC in the nucleus while still allowing DNA-PK nuclear exit, we suggest that EPAC may functionally interact there with Rap2 and be regulated by localized cAMP levels to elicit DNA-PK nuclear exit.
In HeLa, A10, and MEF cells, where EPAC activation triggers nuclear exit of DNA-PK, then EPAC is found localized throughout these cells while Rap2 is localized predominantly to the nucleus (Fig. S7 ). As in HEK-B2 cells, knockdown of Rap2, but not Rap1, ablates the ability of PMT-cAMP ϩ KT5720 challenge to cause DNA-PK nuclear exit in HeLa cells ( ized cAMP signaling determined by targeted degradation through sequestered PDEs (6). Because Ͼ50 different PDEs able to degrade cAMP are expressed in a cell type-specific fashion, this allows considerable latitude in tailoring of cAMP signaling. As a paradigm for assessing the potential for PDEs to confer spatial input control on this process, we have explored the HEK-B2 cell model, where PDE4 enzymes confer the major cAMP-hydrolyzing activity. Indeed, a spatial function has been established for a component of the cytosolic PDE4D activity in HEK-B2 cells (12, 20) , and PDE4 inhibition clearly compromises the isoprenaline-and forskolin-stimulated nuclear exit of DNA-PK mediated by EPAC (Fig. 1) .
In HEK-B2 cells, PDE4B and PDE4D provide 35% and 65%, respectively, of total PDE4 activity, as determined by both selective siRNA-mediated knockdown and selective immunopurification (20) . In these cells, whereas PDE4D is found in the cytoplasm and excluded from the nucleus, the converse is true for PDE4B (Fig. S9) , indicating that such spatially segregated PDE4 subfamilies are poised to exert selective actions. Consistent with this, siRNA-mediated knockdown of nuclear PDE4B caused a profound redistribution of DNA-PK to the cytoplasm whereas, in stark contrast, knockdown of cytoplasmic PDE4D did not (Fig. 3 A and B) . This suggests that when cAMP degradation in the nucleus is compromised by knockdown of PDE4B, this allows formation of a nuclear pool of activated EPAC able to trigger Rap2-mediated DNA-PK nuclear exit (Fig.  3C) . Here, we presume that cytoplasmic PDE4D activity is large enough to prevent localized cAMP levels rising sufficiently so as to activate a PKA population promoting DNA-PK nuclear (re-)entry (Fig. 3C) . We can assess this prediction with simultaneous knockdown of both PDE4B and PDE4D. Consistent with such a hypothesis, no DNA-PK nuclear exit was observed with dual knockdown, which also provides a ''rescue'' control for the PDE4B knockdown experiment (Fig. 3 A and B) . Furthermore, the null effect seen with dual PDE4B/D knockdown mimics the lack of effect seen by using the PDE4-selective inhibitor, rolipram alone ( Fig. 1 D and E) , which will simultaneously inhibit both PDE4B and PDE4D.
Thus, spatially separate PDE4 subpopulations gate the ability of cAMP to modulate the nuclear translocation of DNA-PK in HEK-B2 cells. This involves dual controlling inputs where nuclear PDE4B gates stimulatory control of DNA-PK nuclear exit through EPAC and cytoplasmic PDE4D gates the inhibitory control exerted on this process by PKA in HEK-B2 cells (Fig.  3C) . Given that different cell types vary markedly in their PDE complement, we present the situation in HEK-B2 cells as a paradigm for the potential of compartmentalized cAMP degradation to control the two arms of this process. We would expect this to be tailored in a cell type-specific fashion by the expression of distinct PDE species in different cell types; for example, HeLa cells do not express PDE4B2. Thus, different cell types will be ''wired'' distinctly with regard to control of compartmentalized cAMP signaling by anchored PDEs.
cAMP Regulates the Activity and PKA Phosphorylation Status of DNA-PK. We assessed DNA-PK activity by first immunopurifying it and then taking equal immunoreactive amounts (Fig. S10) to determine its ability to phosphorylate a p53 substrate peptide under various conditions (Fig. 4A) . No significant activity was seen in control experiments using capture beads without antiserum, whereas a basal activity (100%) was evident in resting cells. This was increased Ϸ2-to 3-fold upon challenge of cells with either forskolin or PMT-cAMP. Consistent with EPAC mediating DNA-PK activation, addition of KT5720 failed to block this action of forskolin. Similarly, when forskolin was added in the presence of rolipram, to increase cAMP levels further, DNA-PK activation was ablated. This inhibitory effect was clearly mediated by PKA because KT5720 addition reversed this inhibitory effect of rolipram. We also noted that the siRNA-mediated knockdown of PDE4B, but not PDE4D, led to , and PKA to regulate DNA-PK nuclear/cytoplasmic trafficking. Here, nuclear-localized PDE activity (PDE4B in HEKB2 cells) regulates EPAC/Rap2-mediated DNA-PK nuclear exit, whereas cytosol-localized PDE activity (PDE4D in HEKB2 cells) controls PKA-regulated DNA-PK nuclear (re-)entry. Data shown are typical of experiments done at least three times.
DNA-PK activation. However, as seen with nuclear exit of DNA-PK, the coincident knockdown of both PDE4B and PDE4D failed to elicit DNA-PK activation. This mimics the inability of rolipram addition alone to alter DNA-PK activity. Thus, as with nuclear exit of DNA-PK, its activation ensues upon the selective knockdown of PDE4B in HEK-B2 cells.
Because PKA can regulate both EPAC-mediated DNA-PK activation and nuclear entry of DNA-PK, we set out to explore whether it might phosphorylate DNA-PK. To gain insight into this we exploited an antiserum able to recognize PKA substrates to immunopurify such species from cell lysates and then probe them with a DNA-PK-specific antiserum. By doing so we detected such immunopurified DNA-PK in lysates from cells treated with forskolin ϩ rolipram (Fig. 4B) but not in lysates from either untreated cells or those challenged with either forskolin alone or with PMT-cAMP (Fig. 4B) . Furthermore, exposure of cells to KT5720 prevented such DNA-PK immunopurification from forskolin ϩ rolipram-treated cells (Fig. 4B ).
This finding is consistent with PKA phosphorylating DNA-PK in forskolin ϩ rolipram-treated cells (Fig. 4B) .
DNA-PK sequence analysis by Scansite (21) identifies a robust PKA consensus phosphorylation site and two weaker ones. To see whether these provide potential PKA phosphorylation sites, we generated a library of spot immobilized 25-mer peptides each shifted by 5 residues in the sequence to cover the entire 4,128 amino acids of DNA-PK. This was subjected to phosphorylation with activated PKA catalytic unit and [␥-32 P]ATP (Fig. S11 a and  b) , which clearly showed labeling of peptides that encompassed the clear PKA consensus site at Ser-1790, but not the weaker sites at Ser-893 and Ser-3876. An alanine substitution array showed the consensus RRXS to be critical (Fig. 4C) . These data support the notion that DNA-PK can potentially be phosphorylated by PKA at Ser-1790. Unfortunately, the size of the cDNA (13.5 kbp) encoding this large protein (470 kDa) makes DNA manipulation extremely challenging, and, despite a very considerable effort, we have been unable to generate a S1790A-DNA-PK mutant.
EPAC Activation Triggers the Phosphorylation of PKB/Akt at Ser-473
via DNA-PK. EPAC activation triggers a profound change in the intracellular localization of DNA-PK, but does it alter its downstream functioning?
In observing that PMT-cAMP can activate and relocalize DNA-PK to the cytosol we were cognizant that DNA-PK has been shown able to phosphorylate the cell survival protein kinase, PKB/Akt at Ser-473 at least in certain cell types (22) . Here, we see that forskolin challenge of HEK-B2 cells elicits phosphorylation of PKB/Akt at Ser-473, but not at Thr-308 ( Fig.  5A and Fig. S12a ). As with the nuclear exit of DNA-PK, forskolin-stimulated Ser-473-PKB/Akt phosphorylation was a rapid process and was not attenuated by KT5720 but was mimicked by PMT-cAMP (Fig. S12 b and c) . This is indicative of cAMP activation of DNA-PK by EPAC. Consistent with this, EPAC knockdown, using targeted siRNA (Fig. S6a) , ablated forskolin-stimulated Ser-473-PKB/Akt phosphor ylation (Fig. 5A) .
This process bears comparison with the observed cAMPinduced changes in the nuclear/cytoplasmic distribution of DNA-PK. In both instances, forskolin-stimulated actions were severely compromised upon PDE4 inhibition by rolipram but rescued upon PKA inhibition (Figs. 1 and 5A) . Similarly, both processes were induced by selective PDE4B knockdown but not by either PDE4D knockdown or dual PDE4B/PDE4D knockdown or by total PDE4 inhibition with rolipram alone (Figs. 3 and 5B). Thus, as with nuclear exit of DNA-PK (Fig. 3C) , cAMP exerts dual control on the DNA-PK-mediated phosphorylation of PKB/Akt at Ser-473 in HEK-B2 cells, with stimulation by EPAC gated by PDE4B and inhibition by PKA gated by PDE4D. Likewise, there is a similar requirement for Rap2, rather than Rap1, because forskolin-stimulated Ser-473 phosphorylation of PKB/Akt was abolished upon siRNA-mediated knockdown of Rap2, but not Rap1 (Fig. 5A) .
We undertook a dose-effect study for forskolin-stimulated phosphorylation status of Akt/PKB at Ser-473 (Fig. S12d) . Analyses were done with forskolin alone to provide cAMP access to both EPAC and PKA pathways and with forskolin ϩ KT5720 to access just the EPAC pathway. Here, we identify the EC 50 value for EPAC activation as 162 Ϯ 18 nM (mean Ϯ SD; n ϭ 3 experiments), through assessing the response of forskolin ϩ KT5720. In contrast, subtracting the effect seen with forskolin alone from that observed in the presence of forskolin ϩ KT5720 determines the magnitude of the inhibitory effect of PKA that is generated in a dosedependent fashion by forskolin and negated by KT action. Plotting this yields an IC 50 value of 980 Ϯ 120 nM (mean Ϯ SD; n ϭ 3 experiments). These data demonstrate that stimulatory input into Immunoprecipitates using a PKA substrate-specific antiserum were immunoblotted for DNA-PK and the presence of an immunoreactive species indicating PKA phosphorylation of DNA-PK. (C) After a DNA-PK peptide array was subjected to in vitro phosphorylation by the active PKA catalytic unit, a single discrete cluster of radiolabeled peptides was detected by PhosphorImaging (Fig. S11a) . One of these peptides was chosen whose sequence encompasses Ser-1790, used as a template to generate a family of peptides where each amino acid was sequentially changed to Ala, except for Alal-1786, which was replaced with Asp and the control peptide of sequence indicated. This family of peptides was subjected to phosphorylation as in A with failure of a peptide to undergo phosphorylation indicating the importance of the substituted amino acid. Experiments shown are typical of ones performed on three occasions.
DNA-PK activation through EPAC occurs at lower cAMP concentrations than those needed to elicit inhibitory input via PKA.
In a manner similar to that seen in HEK-B2 cells, treatment of HeLa cells (Fig. S12e) and human neuronal SA121-derived cells (Fig. S4 c and d) with PMT-cAMP increased Ser-473 phosphorylation of PKB/Akt, and this was accentuated in the presence of KT5720, whereas stimulation with forskolin was inhibited by rolipram challenge. The increase seen with PMTcAMP ϩ KT5720 was ablated upon siRNA-mediated knockdown of both EPAC and DNA-PK, indicating that a similar core regulatory system is evident in these cells. However, regulation by PDE activity in these cells will clearly differ from that of HEK-B2 cells because, among various other changes in PDE profile, HeLa cells express no PDE4B2 (data not shown).
A variety of other kinases appear able to phosphorylate PKB/Akt at Ser-473, and their involvement may be determined by their cell type-specific expression patterns and the nature of the stimulatory input. Evidently, the EPAC-triggered Ser-473 phosphorylation of PKB/Akt in the HEK-B2 cell model system is mediated by DNA-PK because its siRNA-mediated knockdown clearly ablated the ability of forskolin to elicit this response (Fig. S13a) . Additionally, we addressed the possible contributions by other kinases implicated in phosphorylation of PKB/Akt at Ser-473 (23) (24) (25) by showing that siRNA-mediated knockdown of either ILK (Fig. S13b) or PKC-␤⌱⌱ (Fig. S13c ) had no effect on the forskolin-stimulated Ser-473-PKB/Akt phosphorylation in HEK-B2 cells.
EPAC and the Repair of Double-Stranded Breaks (DSBs). DNA-PK is well recognized as playing a pivotal role in the repair of DSBs in DNA (18) . This has been well characterized in HeLa cells (26) , a cell line where we have shown here that challenge with EPAC agonist plus a PKA inhibitor causes the marked nuclear exit of DNA-PK. As shown by others (26) , treatment of HeLa cells with etoposide for 1 h causes a profound increase in DSBs that are repaired after 16 h (Fig. 5C) . In contrast to this, whereas treatment of cells with PMT-cAMP ϩ KT5720 did not prevent etoposide forming DSBs, it severely compromised the repair process seen at 16 h (Fig. 5C ). This is consistent with the propensity of PMT-cAMP ϩ KT5720 to promote the nuclear exit of DNA-PK, thereby altering the kinetics of DSB repair while triggering the phosphorylation of PKB/Akt at Ser-473.
Discussion cAMP signaling to the nucleus is usually considered to be the prerogative of PKA, which acts on transcription factors such as cAMP response element-binding protein (2) (3) (4) . Here, we identify a cAMP-controlled signaling pathway that is transduced by EPAC signaling to nuclear-localized Rap2. This leads to the exit of activated DNA-PK from the nucleus where it phosphorylates the cell survival kinase, PKB/Akt at Ser-473. Conversely, cAMP utilizes its traditional effector, PKA, to confer inhibitory regulation on both EPAC-stimulated nuclear exit and activation of DNA-PK (Fig. 3C) . Thus, cAMP exerts dual control on the nuclear/cytoplasmic trafficking of DNA-PK. In such a system, the relative signal strength directed through the two intersecting arms of EPAC and PKA is poised to influence the distribution of DNA-PK between the nuclear and cytoplasmic compartments (Fig. 3C ). This is indicated from the differences in DNA-PK nuclear/cytoplasmic distribution seen in the range of cell types studied here. In HEK-B2 cells, DNA-PK is clearly localized predominantly in the nucleus with EPAC-mediated cytoplasmic accumulation only being attenuated upon activation of the relevant pool of PKA at supramaximal cAMP levels ( Fig. 1 A-E and Fig. S1 c and d) . In contrast, in HeLa cells, the resting level of PKA activity clearly suffices to ablate any effect of EPAC agonist to cause nuclear DNA-PK exit, which is only evident subsequent to PKA inhibition (Fig. S2) . These data suggest that the threshold for activation through EPAC and PKA can be altered on a cell type-specific basis.
It is now well appreciated that cAMP signaling is compartmentalized in cells (2, 4, 6, 27) with intracellular gradients of cAMP being generated by spatially constrained PDE populations of which members of the PDE4 family invariably provide a key role (8, 9) . One means of gating the threshold for activation of EPAC and PKA on this process is to regulate their access to cAMP by PDE-mediated degradation. The expression pattern and targeting of PDE isoforms vary on a cell type-specific basis to tailor cAMP signaling (28) . Our analysis of the model HEK-B2 cell line provides a clear paradigm of the potential to regulate the nuclear/cytoplasmic distribution of DNA-PK through spatially constrained PDE subpopulations. In this cell line, the ability of EPAC to trigger nuclear/cytoplasmic distribution of DNA-PK is primarily gated by the level of cAMP degradation through the cAMP-hydrolyzing activity of PDE4B, which is confined to the nucleus of this cell type where EPAC traffics to interact with Rap2. Indeed, it seems likely that PDE4B protects nuclear located EPAC from inappropriate activation by basal cAMP levels because selective knockdown of PDE4B triggers DNA-PK nuclear exit and Ser-473-PKB/Akt phosphorylation. This means that only when either adenylyl cyclase is activated or nuclear PDE is selectively inhibited will cAMP levels rise sufficiently to allow for EPAC to be active in the nucleus. A brake on DNA-PK nuclear exit and its ability to phosphorylate PKB at Ser-473 is applied by PKA. This inhibitory effect is also compartmentalized, being gated by a cytoplasmic PDE, which in HEK-B2 cells is PDE4D (Fig. 3C) . This process likely underpins observations of various investigators indicating that EPAC can elicit Akt/PKB activation (29, 30) .
Our data provide a functional role for the observation of Cheng and coworkers (17) , who showed that a fraction of EPAC can locate to the nucleus. Thus, the EPAC/Rap2-transduced nuclear exit of active DNA-PK offers the potential for cAMP to control the action of DNA-PK on a whole new set of substrates and regulating its ability to mediate actions within the nucleus through relocalization to the cytoplasm. It seems likely that such effects may primarily be mediated by EPAC1 in HEKB2 and HeLa cells based on molecular size.
Here, then, we identify the dual control of DNA-PK nuclear exit through intersecting, antagonistic cAMP signaling processes. This process can be regulated by compartmentalization of cAMP degradation through spatially segregated pools of PDE. Although this process is evident in a number of cell types it clearly depends critically on the expression and spatial targeting of a number of key proteins. Because there is much interest in developing DNA-PK inhibitors for enhancing radiosensitivity of tumor cells in cancer chemotherapy (31) , it will be of interest to see whether cAMP-induced nuclear exit of DNA-PK can contribute to this.
Methods
Sourcing of reagents, cell culture, transfections, Western blotting, immunoprecipitation, immunocytochemistry, image analysis, and siRNA generation were done as described in detail (12, 20) . DNA-PK activity was determined by using the SigmaTECT DNA-PK assay system (Promega) with equal immunoreactive amounts of immunopurified DNA-PK. Analysis of peptide libraries was done as described with phosphorylation initiated by using 70 units of recombinant PKA catalytic subunit (13) . DSBs were assessed by phosphorylated H2AX formation in HeLa cells grown to 50 -70% confluence on glass coverslips with Metamorph quantification (26) . Additional details are given in SI Methods.
